findmyKOL
Clinical trialNCT00741403CompletedPhase 1Interventional

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

SponsorCornerstone PharmaceuticalsEnrollment39Advanced CancerAdvanced MalignanciesLymphomaMetastatic CancerSolid Tumors
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

United States
  • Pivotal Research Centers

    Peoria, Arizona, United States

  • Eastchester Center for Cancer Care

    The Bronx, New York, United States

  • Mary Crowley Cancer Research Centers

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2008
Primary completion
31 Dec 2016
Completion
31 Dec 2016
Last update posted
29 Dec 2016
Registered enrollment
39
Registry id
NCT00741403

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.